First Time Loading...
I

Intra-Cellular Therapies Inc
NASDAQ:ITCI

Watchlist Manager
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Watchlist
Price: 65.32 USD 0.49% Market Closed
Updated: May 21, 2024

P/E
Price to Earnings

-57.4
Current
-17.1
Median
23.5
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-57.4
=
Market Cap
6.4B
/
Net Income
-110.9m
All Countries
Close
Earnings Growth
US
I
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Average P/E: 55.1
Negative Multiple: -57.4
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
121.3
346%
DK
Novo Nordisk A/S
CSE:NOVO B
45.5
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.5
-21%
US
Merck & Co Inc
NYSE:MRK
143.9
7 453%
UK
AstraZeneca PLC
LSE:AZN
38
168%
CH
Roche Holding AG
SIX:ROG
16.4
26%
CH
Novartis AG
SIX:NOVN
11.4
15%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -523.2
680%

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-86.7
2-Years Forward
P/E
46.5
3-Years Forward
P/E
14.4

See Also

Discover More